Search Results - Stephan Linden

  • Showing 1 - 6 results of 6
Refine Results
  1. 1

    Resource utilisation and outcomes of people with heart failure in England: a descriptive analysis of linked primary and secondary care data – the PULSE study by Nicholas D Gollop, Stephan Linden, Ruth Farmer

    Published in Open Heart (2023-11-01)
    Get full text
    Article


  2. 2

    Cost-effectiveness of empagliflozin in the treatment of Malaysian patients with chronic heart failure and preserved or mildly reduced ejection fraction by Yi Jing Tan, Stephan Linden, Siew Chin Ong

    Published in PLoS ONE (2024-01-01)
    Get full text
    Article


  3. 3

    Cost-effectiveness of adding empagliflozin to the standard of care for patients with heart failure with reduced ejection fraction from the perspective of healthcare system in Malay... by Siew Chin Ong, Joo Zheng Low, Joo Zheng Low, Stephan Linden

    Published in Frontiers in Pharmacology (2023-06-01)
    Get full text
    Article


  4. 4

    Cost‐Effectiveness Analysis of Empagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction in the United States by Odette S. Reifsnider, Ali Tafazzoli, Stephan Linden, Jack Ishak, Pal Rakonczai, Matthew Stargardter, Effie Kuti

    Get full text
    Article


  5. 5

    Multinational cost‐effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40% by Spyros Kolovos, Leana Bellanca, Harinala Groyer, Giuseppe M.C. Rosano, Alexandra Solé, Jennifer Gaultney, Stephan Linden

    Published in ESC Heart Failure (2023-12-01)
    Get full text
    Article


  6. 6

    Empagliflozin cost‐effectiveness analysis in Japanese heart failure with mildly reduced and preserved ejection fraction by Hiroyuki Tsutsui, Hiroyuki Sakamaki, Shin‐ichi Momomura, Yasushi Sakata, Yutaro Kotobuki, Stephan Linden, Koki Idehara, Daisuke Nitta

    Published in ESC Heart Failure (2024-02-01)
    Get full text
    Article


Search Tools: